Every 8-K that Firefly Neuroscience, Inc. (AIFF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AIFF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIFF filings page.
Firefly Neuroscience, Inc. held its 2026 annual meeting on August 5, 2026, where stockholders approved Amendment No. 2 to the 2024 Long-Term Incentive Plan, increasing the Plan Share Limit by 2,000,000 shares of common stock and updating the plan’s evergreen provision. Stockholders also elected Arun Menawat as a Class III director to serve until 2029 and approved, on a non-binding advisory basis, compensation for named executive officers.
Stockholders approved a charter amendment decreasing total authorized capital from 5,001,000,000 shares to 101,000,000, consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock, effective August 5, 2026. They ratified CBIZ Canada, LLP as independent auditor and approved an adjournment proposal. Shares outstanding on the June 8, 2026 record date were 15,604,571, with 9,703,536 shares represented, constituting a quorum.
Firefly Neuroscience, Inc. has terminated a previously agreed financing deal. The company and an accredited investor mutually ended a securities purchase agreement dated May 6, 2026, under which Firefly had planned to sell up to 666,667 units at $1.50 per unit, for potential gross proceeds of up to $1,000,000. The termination was agreed in writing and became effective on June 25, 2026, under Section 5.3 of the agreement. This update is reported as the termination of a material definitive agreement.
Firefly Neuroscience, Inc. reports a change in the role and status of former Chief Technology Officer Gil Issachar. On June 18, 2026, Deel Innovation Ltd., which provides consulting services to Firefly, entered into an employment agreement with Issachar under which he now serves as Head of AI and Neuroscience for the company.
The new agreement supersedes all prior employment terms between Firefly and Issachar. Effective June 18, 2026, the board determined that Issachar is no longer classified as a Section 16 officer or executive officer of Firefly Neuroscience. The employment agreement is filed as Exhibit 10.1.
Firefly Neuroscience, Inc. entered into a securities purchase agreement with an accredited investor for a private placement of up to 666,667 units at $1.50 per unit, for aggregate gross proceeds of up to $1,000,000. Each unit includes one share of common stock plus two five-year warrants, one exercisable at $1.88 per share and the other at $2.50 per share.
The warrants carry beneficial ownership limits of 4.99% or 9.99% and are not exercisable until stockholders approve the warrant share issuance. The closing depends on both stockholder approval and effectiveness of a resale registration statement on Form S-1 (or similar) covering the shares and warrant shares.
Firefly Neuroscience, Inc. completed an additional private financing closing, issuing 5,333,333 Units to an accredited investor for a total purchase price of $8,000,000 at $1.50 per Unit under its existing Securities Purchase Agreement.
The company and all investors entered into an Amended and Restated Lock-Up Agreement, restricting transfers of specified securities for a 30-day period ending on May 16, 2026, after which the lock-up securities will be fully released. In connection with this closing, investors also agreed to extend the deadline for the company to file a related Registration Statement with the SEC to May 21, 2026, with targeted effectiveness within 45 or 90 days after filing, depending on SEC review.
Firefly Neuroscience, Inc. entered a private securities purchase agreement with accredited investors, raising an initial $2,250,000 through 1,500,000 Units at $1.50 per Unit. Investors also have the right to make up to an additional $18,000,000 in Unit purchases within 30 days after the initial closing.
Each Unit includes either one share of common stock or a pre-funded warrant, plus two five-year warrants exercisable at $1.88 and $2.50 per share, subject to 4.99% or 9.99% beneficial ownership limits. The transaction was priced at the Nasdaq Minimum Price and structured to comply with Nasdaq Listing Rule 5635(d) without stockholder approval.
The company agreed to file a resale registration statement for the shares and warrant shares by April 15, 2026, and to seek its effectiveness within set SEC review timelines. Investors are subject to a six-month lock-up on their securities through September 12, 2026, followed by a six-month leak-out period through March 12, 2027, with monthly incremental releases.
Firefly Neuroscience, Inc. entered into an at-the-market equity offering agreement with Konik Capital Partners, LLC, allowing the company to sell shares of common stock with an aggregate offering price of up to $7,434,266 on Nasdaq or other markets. Konik will act as sales agent or principal, earning a 2.0% commission on gross proceeds and reimbursement of specified legal and diligence costs. The shares are being offered under Firefly’s effective Form S-3 shelf registration and a February 3, 2026 prospectus supplement, and the company currently intends to use net proceeds for working capital and general corporate purposes.
Separately, a wholly owned subsidiary amended the employment agreement of Chief Technology Officer Gil Issachar, replacing his automatic annual bonus with eligibility for a discretionary annual bonus of up to one month of gross salary and providing for payment of outstanding bonuses accrued through December 31, 2025.
Firefly Neuroscience, Inc. (AIFF) reported final results from its 2025 annual meeting and a reconvened session. Stockholders elected two Class II directors and ratified Marcum Canada, LLP as auditor. They approved an amendment to the 2024 Long‑Term Incentive Plan to add 317,820 shares and adopt an annual increase equal to the lower of 4% of shares outstanding or a Board‑set amount from January 1, 2026 through January 1, 2035.
At the reconvened meeting on October 31, 2025, stockholders approved a charter amendment increasing authorized shares to 5,001,000,000 (5,000,000,000 common; 1,000,000 preferred), with votes For 6,185,466, Against 1,303,224, Abstain 142,460. Earlier proposals passed with strong support, including auditor ratification (For 7,044,440). Shares outstanding were 13,448,848 as of September 4, 2025, and quorum was met at both sessions.